Cargando…

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

(177)Lu-DOTA-HH1 ((177)Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of (177)Lu-HH1, (177)Lu-DOTA-rituximab ((177)Lu-rituximab) and non-specific (177)Lu-DOTA-IgG(1) ((177)Lu-Ig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Repetto-Llamazares, Ada H. V., Larsen, Roy H., Patzke, Sebastian, Fleten, Karianne G., Didierlaurent, David, Pichard, Alexandre, Pouget, Jean Pierre, Dahle, Jostein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466226/ https://www.ncbi.nlm.nih.gov/pubmed/26066655 http://dx.doi.org/10.1371/journal.pone.0128816

Ejemplares similares

Biodistribution and Dosimetry of (177)Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H V, et al.
Publicado: (2013)

Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2019)

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate (212)Pb-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2020)

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

Anti-CD37 radioimmunotherapy with (177)Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
por: Malenge, Marion M., et al.
Publicado: (2022)

Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
por: Aurlien, E, et al.
Publicado: (2000)

The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
por: Pichard, Alexandre, et al.
Publicado: (2019)

(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2014)

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
por: Rødland, Gro Elise, et al.
Publicado: (2019)

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma
por: Hull, Ashleigh, et al.
Publicado: (2022)

FDG PET/CT and Dosimetric Studies of (177)Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?
por: Løndalen, Ayca, et al.
Publicado: (2022)

Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
por: Sharma, Sai Kiran, et al.
Publicado: (2021)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
por: Stokke, Caroline, et al.
Publicado: (2018)

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of (177)Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
por: Løndalen, Ayca, et al.
Publicado: (2020)

(89)Zr-PET imaging to predict tumor uptake of (177)Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
por: Giesen, Danique, et al.
Publicado: (2022)

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate
por: Qu, C F, et al.
Publicado: (2004)

Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting (227)Th-DOTA-p-benzyl-trastuzumab
por: Heyerdahl, Helen, et al.
Publicado: (2012)

$\beta$-decay of $^{37}$Ca
por: Trinder, W, et al.
Publicado: (1994)

Synthesis and In Vivo Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas
por: Pringle, Toni A., et al.
Publicado: (2022)

Proteomic Identification of Plasma Biomarkers in Children and Adolescents with Recurrent Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2018)

Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma
por: De Re, Valli, et al.
Publicado: (2022)

Primary gastric Hodgkin's lymphoma
por: Hossain, Fahad S, et al.
Publicado: (2007)

$\beta^{+}$ decays of $^{37}$Ca: implications for the efficiency of the $^{37}$Cl solar $\nu$ detector
por: García, A, et al.
Publicado: (1991)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

BRAF mutations in non-Hodgkin's lymphoma
por: Lee, J W, et al.
Publicado: (2003)

Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas.
por: Johnson, P. W., et al.
Publicado: (1993)

Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Non-Hodgkin's Lymphomas
por: Proctor, S.J.
Publicado: (1994)

EBV in Hodgkin Lymphoma
por: Massini, Giuseppina, et al.
Publicado: (2009)

Pathobiology of Hodgkin Lymphoma
por: Piccaluga, Pier Paolo, et al.
Publicado: (2011)

Pathobiology of Hodgkin Lymphoma
por: Agostinelli, Claudio, et al.
Publicado: (2014)

Cutaneous Hodgkin's lymphoma
por: Ambekar, Asawari Anant, et al.
Publicado: (2017)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Lymphocyte markers in non-Hodgkin's lymphomas.
por: Payne, S. V., et al.
Publicado: (1977)

Primary non-Hodgkin lymphoma of liver
por: Masood, A., et al.
Publicado: (2009)

Association of HHV-6 with Hodgkin and non Hodgkin lymphoma
por: Kiani, Hadis, et al.
Publicado: (2016)

Rare Richter Transformation of Chronic Lymphocytic Lymphoma to Hodgkin Lymphoma
por: Buckley, Tinera, et al.
Publicado: (2021)

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
por: Hicks, Stuart W., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mbh60mh774ibkrhaj5khfd7bfh